Abbott Laboratories $ABT Shares Acquired by Lbp Am Sa

Lbp Am Sa lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 59.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,182 shares of the healthcare product maker’s stock after buying an additional 17,282 shares during the period. Lbp Am Sa’s holdings in Abbott Laboratories were worth $6,186,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. IMG Wealth Management Inc. raised its position in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Anfield Capital Management LLC lifted its stake in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the second quarter valued at $32,000. Curio Wealth LLC increased its holdings in shares of Abbott Laboratories by 15,250.0% in the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock worth $42,000 after acquiring an additional 305 shares during the period. Finally, Pineridge Advisors LLC lifted its position in Abbott Laboratories by 34.6% in the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock valued at $43,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s chairman, Robert B. Ford, bought $2 million of ABT stock — an insider buy that signals management confidence. Chairman Buys $2M in ABT
• Positive Sentiment: Evercore ISI reiterated an Outperform rating and said Abbott’s core growth drivers remain intact despite trimming its price target to $138 — supportive analyst view even after the quarter. Evercore: Core Growth Drivers Intact
• Positive Sentiment: Market momentum: Abbott snapped six straight sessions of losses, which can attract short‑covering and momentum buyers. ABT Snaps Losing Streak
• Positive Sentiment: Bullish analysis: At least one analyst piece highlights double‑digit earnings growth potential, reinforcing longer‑term upside narratives. Double‑Digit Earnings Growth Thesis
• Neutral Sentiment: Stock is a trending/searched ticker on retail platforms, drawing attention from momentum traders and retail buyers. Zacks: Trending Stock
• Neutral Sentiment: Commentary pieces ask whether January’s pullback is a buying opportunity, keeping ABT in retail and advisor conversations. Is the Pullback a Buy?
• Neutral Sentiment: Roundups of hedge‑fund and insider activity mention ABT among other names — informational but not clearly directional. Hedge Fund & Insider News
• Negative Sentiment: Multiple sell‑side firms trimmed price targets or issued cautious/pessimistic forecasts after the quarter (reduced revenue vs. expectations and cautious guidance). Notable items include cuts/negative notes from Royal Bank of Canada, Citigroup, Goldman Sachs, Sanford C. Bernstein and others — a headwind for near‑term sentiment. RBC Lowers PT to $135 Citigroup Pessimistic Forecast Goldman Sachs Negative Note

Abbott Laboratories Price Performance

ABT opened at $108.79 on Tuesday. Abbott Laboratories has a 12-month low of $105.78 and a 12-month high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $189.18 billion, a P/E ratio of 29.25, a PEG ratio of 1.78 and a beta of 0.72. The stock has a fifty day moving average of $124.34 and a 200-day moving average of $128.12.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several research analyst reports. Wells Fargo & Company upped their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Mizuho raised their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday. The Goldman Sachs Group decreased their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Finally, Daiwa Capital Markets upped their target price on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $140.79.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.